Article Text

Download PDFPDF
IKKβ as a target for treatment of inflammation induced bone loss
  1. M G Ruocco,
  2. M Karin
  1. Laboratory of Gene Regulation and Signal Transduction, School of Medicine, University of California at San Diego, La Jolla, CA, USA
  1. Correspondence to:
    M Karin
    karinofficeucsd.edu

Abstract

The transcription factor nuclear factor (NF)-κB is well recognised as a pivotal player in osteoclastogenesis and inflammation induced bone loss. Here, the authors discuss their recent results, obtained using a genetic approach in mice, that indicate the importance of IKKβ, and not IKKα, as a transducer of signals from receptor activator of NF-κB (RANK) to NF-κB. Ablation of IKKβ results in lack of osteoclastogenesis and unresponsiveness of IKKβ deficient mice to inflammation induced bone loss. In the need of a more effective therapy for the treatment of inflammatory diseases causing bone resorption, specific inhibition of IKKβ represents a logical alternative strategy to the current therapies.

  • IKK, IκB kinase
  • IL, interleukin
  • LPS, lipopolysaccharide
  • OPG, osteoprotegerin
  • RA, rheumatoid arthritis
  • RANKL, receptor activator of nuclear factor (NF)-κB ligand
  • TNF, tumour necrosis factor
  • TNF-R, TNF receptor
  • IKKβ
  • bone loss
  • inflammation
  • NF-κB

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Competing interests: none declared